Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties

Artificial Organs

Volumn 34, Issue 10, 2010, Pages 836-845

  Liu, Yaqin ^a   Jiang, Zhaoxin ^a   Gao, Qianying ^a   Ge, Jian ^a   Chen, Jiajia ^a   Cao, Xianwu ^b   Shen, Qingxiang ^b   Ma, Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Artificial vitreous body; Capsule; Liquid silicone rubber

Indexed keywords

CELL DEATH; OPTICAL PROPERTIES; SILICONE RUBBER; TENSILE STRENGTH;

ARTIFICIAL VITREOUS BODY; CAPSULE; LIQUID SILICONE RUBBERS; MECHANICAL; OPTICAL-; PHYSIOLOGIC FUNCTION; PROPERTY; TECHNICAL STANDARDS; VITREOUS BODY; VITREOUS SUBSTITUTE;

BIOCOMPATIBILITY;

BIOMATERIAL; SILICONE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ARTIFICIAL ORGAN; BIOCOMPATIBILITY; CILIARY BODY; CONTROLLED STUDY; CORNEA; FOLDABLE CAPSULAR VITREOUS BODY; NONHUMAN; OPTICAL INSTRUMENTATION; POROSITY; PRIORITY JOURNAL; RETINA; VITREOUS BODY;

ORYCTOLAGUS CUNICULUS;

EID: 77958579775     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2010.01006.x     Document Type: Article

References (33)

1. Yeh S, Colyer MH, Weichel ED. Current trends in the management of intraocular foreign bodies. Curr Opin Ophthalmol 2008;19:225-33.
2. Augustin AJ, Offermann I. Scope and limititions of innovative vitrectomy systems. Klin Monbl Augenheilkd 2007;224:707-15.
3. Chaudhry NA, Cohen KA, Flynn HW Jr, Murray TG. Combined pars plana vitrectomy and lens management in complex vitreoretinal disease. Semin Ophthalmol 2003;18:132-41.
4. Gafencu O. Surgical principles and techniques in severe proliferative diabetic retinopathy. Oftalmologia 2001;52:54-7.
5. Castellarin A, Grigorian R, Bhagat N, Del Priore L, Zarbin MA. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 2003;87:318-21.
6. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998;43:3-18.
7. Quiram PA, Gonzales CR, Hu W, et al. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology 2006;113:2041-7.
8. Cibis PA, Becker B, Okun E, Canaan S. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol 1962;68:590-9.
9. The Silicone Study Group. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 1992;110:770-9.
10. Azen SP, Scott IU, Flynn HW, et al. Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study. Ophthalmology 1998;105:1587-97.
11. Scott IU, Flynn HW Jr, Murray TG, Smiddy WE, Davis JL, Feuer WJ. Outcomes of complex retinal detachment repair using 1000- vs 5000-centistoke silicone oil. Arch Ophthalmol 2005;123:473-8.
12. Lam RF, Cheung BT, Yuen CY, Wong D, Lam DS, Lai WW. Retinal redetachment after silicone oil removal in proliferative vitreoretinopathy: a prognostic factor analysis. Am J Ophthalmol 2008;145:527-33.
13. Bhisitkul RB, Gonzalez VH. "Heavy oil" for intraocular tamponade in retinal detachment surgery. Br J Ophthalmol 2005;89:649-50.
14. Mackiewicz J, Mühling B, Hiebl W, et al. In vivo retinal tolerance of various heavy silicone oils. Invest Ophthalmol Vis Sci 2007;48:1873-83.
15. Hong Y, Chirila TV, Fitton JH, Ziegelaar BW, Constable IJ. Effect of crosslinked poly (1-vinyl-2-pyrrolidinone) gels on cell growth in static cell cultures. Biomed Mater Eng 1997;7:35-47.
16. Hong Y, Chirila TV, Vijayasekaran S, Shen W, Lou X, Dalton PD. Biodegradation in vitro and retention in the rabbit eye of crosslinked poly (1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute. J Biomed Mater Res 1998;39:650-9.
17. Maruoka S, Matsuura T, Kawasaki K, et al. Biocompatibility of polyvinylalcohol gel as a vitreous substitute. Curr Eye Res 2006;31:599-606.
18. Wong D, Lois N. Perfluorocarbons and semifluorinated alkanes. Semin Ophthalmol 2000;15:25-35.
19. Peyman GA, Schulman JA, Sullivan B. Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol 1995;39:375-95.
20. Colthurst MJ, Williams RL, Hiscott PS, Grierson I. Biomaterials used in the posterior segment of the eye. Biomaterials 2000;21:649-65.
21. Soman N, Banerjee R. Artificial vitreous replacements. Biomed Mater Eng 2003;13:59-74.
22. Green WR, Sebag J. Vitreoretinal interface. In: Ryan SJ, ed. Retina. Maryland Heights (MO): Elsevier Mosby, 2006;1921-89.
23. Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve. Eye 2008;22:461-8.
24. Gao Q, Chen X, Ge J, et al. Refractive shifts in four selected artificial vitreous substitutes based on Gullstrand-Emsley and Liou-Brennan schematic eyes. Invest Ophthalmol Vis Sci 2009;50:3529-34.
25. Gao Q, Liu Y, Ke Q, et al. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body. Invest Ophthalmol Vis Sci 2010;51:1636-42.
26. Determination of indentation hardness-part 1: durometer method (shore hardness). In: ISO 7619-1-2004: Rubber, Vulcanized or Thermoplastic.
27. Determination of tear strength-part 1: trouser, angle and crescent test pieces. In: ISO 34-1-2004: Rubber, Vulcanized or Thermoplastic.
28. Determination of tensile stress-strain properties. In: ISO 37-2005 Rubber, Vulcanized or Thermoplastic.
29. Determination of the total luminous transmittance of transparent materials-part 2: double beam instrument. In: ISO 13468-2-1999: Plastics.
30. Determination of haze for transparent materials; technical corrigendum 1. In: ISO 14782 Technical Corrigendum 1-2005: Plastics.
31. Intraocular lenses-part 2: optical properties and test methods. In: ISO 11979-2-1999: Ophthalmic Implants.
32. Toxicology Sub-Group of the Tripartite Sub-Committee on Medical Devices. Tripartite biocompatibility guidance for medical devices. 1986. (ISO 10993-1:1992(E): biological evaluation of medical devices-Part 1: guidance on Selection of Tests. Geneva Switzerland: International Organization for Standardization).
33. Part 3: tests for genotoxicity, carcinogenicity, and reproductive toxicity. In: ISO 10993-3:2003: Biological Evaluation of Medical Devices.